🔗 Share this article

As America proceeds with unprecedented revisions to its vaccine recommendations, one figure has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by casting doubt on coronavirus vaccinations during the pandemic and has focused upon possible fatalities after COVID-19 vaccination in her brief tenure at the Food and Drug Administration.

Planned Shifts to Pediatric Vaccine Schedule

Health officials planned to reveal major revisions to the childhood vaccination calendar earlier this month, synchronizing the US with the Danish immunization schedule, sources say – a significant shift that would place the US out of alignment with much of the global community with insufficient data for benefit. The announcement has been pushed back until the new year.

Rather than the director of the vaccine center, Høeg is listed to address the audience at the meeting. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth appointee to run the center this calendar year.

Consolidating Power at the FDA

The acting appointment may indicate a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it suggests a renewed priority upon rolling back previously authorized vaccines at the FDA.

The new acting director has frequently advocated for ending certain pediatric immunization guidelines in the US to become more similar to Denmark's approach, a nation with universal health coverage and a population approximately the size of Wisconsin’s.

To date public appearances, she has continued to focus on vaccines – typically the responsibility of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Questions Over Background

Dr. Høeg has little discernible background in pharmaceutical research, regulation or leadership, which has been customary for past heads of the CBER. She has served at the FDA as a top consultant to the FDA chief and CBER since March.

“She appears not to have the requisite experience” for overseeing the drug-regulation department, remarked Dr. Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in leading a large organization. She has no expertise in industry regulation.”

Previous commissioners of CBER would “be deeply familiar with laws and regulations and the science of drug development”, said Dr. Janet Woodcock. “Frankly, she lacks the sort of resume that prior appointees who ran the center have had.”

The drug center has an vast workload at the agency, she pointed out.

“The public just zeroes in on the novel medication approvals, but the generic drug division approves numerous generic medications. There’s a biosimilars division, over-the-counter program and more, and every single one have to be supervised,” Woodcock noted. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a substantial leadership component to the job, which oversees in excess of 5,000 personnel. “It’s a huge administrative position, if you do it right,” Woodcock concluded.

Agency Reaction and Disputed Policies

Regarding inquiries about Dr. Høeg's credentials and whether this selection represents greater collaboration among agency officials on immunizations, a spokesperson said that the “questions rely on incorrect presumptions”.

“Her experience matches the functions of her job,” the official explained, noting the time Høeg spent counseling the agency head on “drug safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As acting director, Dr. Høeg assumes responsibility for the agency head's controversial priority voucher program, a disputed one-day therapy clearance system that apparently worried her predecessors. “By what process are these therapies being chosen for this voucher program? Who makes the calls?” Dr. Howard questioned. “There is a lot of secrecy happening at the FDA right now.”

Broadly speaking, he remarked, “the FDA seems to be moving towards more relaxed regulations of pharmaceuticals, except for shots.”

Established History on Immunizations

Concerning immunizations, Høeg has a more established, if troubling, track record, some experts said. She published a research paper using non-validated crowd-sourced reports to determine the frequency of myocarditis after COVID-19 immunization. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to indicate Covid vaccines are pose a greater threat than they are.

Part of her “wish list” for the new administration featured revising rules for new vaccines and ending “non-essential” immunizations, she remarked following the vote on a online show. At the FDA, Høeg has allegedly floated the idea of preventing teenage boys from obtaining COVID-19 vaccinations.

“She is an all-around ideologue who commences with her preconceived notions and reverse-engineers to fit the science in a very disingenuous, fraudulent fashion,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg became part of other skeptics, {like|